Phase 2 N=65 Pembrolizumab in Treating Patients With Malignant Mesothelioma
Biphasic Mesothelioma · Epithelioid Mesothelioma · Peritoneal Malignant Mesothelioma
Primary: Ability of PD-L1 to Predict Response — 0.377 Youden index
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=39 Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma
Advanced Malignant Mesothelioma · Recurrent Malignant Mesothelioma
Primary: Objective Response (Partial and Complete) Per RECIST — 1 participants
Phase 2 N=45 SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma
Mesothelioma · Adenocarcinoma of Lung · Pancreatic Neoplasms
Primary: Response Assessment — 0; 0; 0; 0 Participants
Phase 2 N=34 Pazopanib in Treating Patients With Malignant Pleural Mesothelioma
Advanced Malignant Mesothelioma · Localized Malignant Mesothelioma · Recurrent Malignant Mesothelioma
Primary: Proportion of Evaluable Participants Who Are Progression-free at 6 Months Based on the Response Evaluation Criteria for Solid Tumors (RECIST) — 47.8 percentage of…
Phase 2 N=32 Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma
Mesothelioma
Primary: Best Overall Response by RECIST Criteria (Version 1.0) — 3; 0; 7; 6 eligible, treated participants
Phase 2 N=31 Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen
Non-small Cell Lung Cancer · Mesothelioma · Lung Neoplasms
Primary: Overview of Adverse Events — 28; 23; 12; 1 participants
Phase 3 N=520 Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
Mesothelioma
Primary: Phase II: Progression Free Survival Measured as Time From Randomization to First Observation of Objective Disease Relapse or Progression — 6.7; 6.8; 5.26 months
Phase 2 N=53 Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy
Malignant Mesothelioma
Primary: Progression-free Survival — 3.0; 3.4 months
Phase 3 N=144 PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma
Pleural Mesothelioma Malignant Advanced
Primary: Progression Free Survival (PFS) as Assessed by Independent Radiological Review — 2.5; 3.4 months — p=0.76
Phase 2 N=77 Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma
Pleural Neoplasms
Primary: Pathological Complete Response — 3 participants
Phase 2 N=43 Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma
Malignant Mesothelioma
Primary: 24 Week Progression Free Survival — 23 percentage of participants
Phase 3 N=400 BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma
Pleural Mesothelioma Malignant Advanced
Primary: Overall Survival (OS) — 20.5; 18.1 months — p=0.14
Phase 3 N=72 Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer
Malignant Pleural Effusion
Primary: Number of Participants With "Complete Response" and "Partial Response" — 17; 2; 13; 15 participants
Phase 1 N=24 Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma
Pleural Malignant Mesothelioma
Primary: Safety/Toxicity — 0; 0 participants
Phase 2 N=89 An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
Malignant Pleural Mesothelioma
Primary: Number of Participants With Progression Free Survival (PFS) Responders and Non-responders at Month 6 — 26; 51 Participants
Phase 2 N=61 S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Malignant Mesothelioma
Primary: Progression-Free Survival — 3.0 months
Phase 2 N=24 MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
Mesothelioma
Primary: Change in Ratio of Intratumoral Cytotoxic T Cells to Regulatory T Cells (CD8/Treg) — 8.6 no unit of ratios with same units(%) — p=0.109
Phase 2 N=2 Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma
Malignant Peritoneal Mesothelioma
Primary: Objective Response Rate
Phase 2 N=23 Olaparib in People With Malignant Mesothelioma
Mesothelioma
Primary: Number of Participants With an Objective Response — 1; 0; 0; 0 Participants
Phase 1 N=12 Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma
Leukemia · Lung Cancer · Malignant Mesothelioma
Primary: Safety — 10 participants
Phase 1 N=21 Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma
Mesothelioma
Primary: Recommended Phase 2 Dose (RP2D) of LMB100 + Nab-paclitaxel — 140; 100 mcg
Phase 2 N=54 S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery
Advanced Malignant Mesothelioma · Epithelial Mesothelioma · Recurrent Malignant Mesothelioma
Primary: Overall Response Rate — 9 percentage of participants
Phase 2 N=51 Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery
Advanced Malignant Mesothelioma · Epithelial Mesothelioma · Localized Malignant Mesothelioma
Primary: Objective Response Rate, Complete (CR) or Partial (PR) Response — 5 percentage of participants
Phase 2 N=41 Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy
Malignant Pleural Mesothelioma
Primary: 1-year Progression-free Survival — 44; 33 percentage of participants
Phase 2 N=20 Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy
Pleural Mesothelioma · Peritoneal Mesothelioma
Primary: Clinical Response Rate (PR+CR) — 0; 0 Participants
N/A N=25 Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer
Lung Cancer
Primary: Number of Red Fluorescent [i.e., Cancer] Cells (RFCs) in Sputum From Healthy Participants — 0 number of RFCs per participant
Phase 2 N=53 Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
Mesothelioma
Primary: Progression Free Survival Rate at 6 Months — 56 percentage of participants
Phase 2 N=55 Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma
Mesothelioma · Pleural Mesothelioma
Primary: Overall Survival (OS) — 20.4 months
Phase 2 N=15 Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma
Malignant Mesothelioma (MPM)
Primary: Overall Response Rate — 2; 8; 1; 4 Participants
Phase 2 N=71 Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Lung Cancer
Primary: Mediastinal Nodal Clearance After Completion of Induction Chemoradiotherapy With or Without Panitumumab. — 68.2; 48.7 percentage of participants — p=0.96